National Recognition: magAssist Certified as a High-Tech Enterprise, Strengthening the Foundation of Domestic Multi-Organ Life Support Innovation

Recently, the Jiangsu Provincial Certification Authority officially released the first batch of enterprises recognized as High-Tech Enterprises in 2025. magAssist (Suzhou) Co., Ltd. has been successfully included on the list.

The High-Tech Enterprise certification is a national-level, authoritative qualification in China, granted to companies demonstrating strong capabilities in independent core technology R&D, commercialization of scientific achievements, and sustainable innovation capacity. This recognition affirms magAssist's comprehensive strength across proprietary technology development, industrialization of innovation, and value creation within the domestic healthcare system.

Combined with the company's five consecutive years of selection as a "Jiangsu Potential Unicorn Enterprise," this milestone reflects both national- and provincial-level recognition of magAssist's progress in advancing localized multi-organ life support technologies, reinforcing its role in promoting high-quality, self-reliant development of China's medical device industry.

magAssist Recognized as a High-Tech Enterprise

The High-Tech Enterprise evaluation focuses on key indicators including R&D investment intensity, core intellectual property ownership, and technology commercialization capability, serving as an important benchmark of a company's innovation strength.

Since its establishment, magAssist has remained committed to addressing unmet domestic clinical needs, overcoming technical barriers in critical medical technologies, and advancing independent controllability and localization. Leveraging Jiangsu's robust medical innovation ecosystem, the company follows an integrated clinician–engineer collaboration model, aligning closely with the criteria of High-Tech Enterprise certification.

Under the leadership of Dr. Po-Lin Xu, Founder and CEO, who brings over two decades of experience in artificial heart technologies and a strong international academic background, magAssist has built a multidisciplinary innovation platform that integrates global engineering expertise with real-world clinical demands in China.

In intellectual property development, magAssist has filed over 400 patent applications, with core patents addressing key domestic technology gaps. Most patents filed in the past two years support the iteration and industrialization of localized products. In parallel, the company has established international patent portfolios in the United States, Europe, and other regions, extending the validation of its technical capabilities globally.

The company has also undertaken provincial technology achievement transformation projects and established long-term collaborations with multiple clinical centers, forming an efficient "R&D – clinical application – commercialization" cycle with industry-leading conversion efficiency.

From Innovation to Impact: Industrialization of Multi-Organ Life Support Solutions

Behind this certification lies magAssist's tangible progress in the domestic multi-organ life support field:

• MoyoAssist®, a fully magnetically levitated extracorporeal ventricular assist device, has received approval from the National Medical Products Administration (NMPA), breaking longstanding reliance on imported technologies and being included in reimbursement programs across multiple provinces and cities.

• BreathMo®, a new-generation portable ECMO system, has received provincial funding support for technology transformation and has been deployed in large-scale emergency scenarios, including the Hangzhou Asian Games, demonstrating adaptability to diverse emergency care settings.

• NyokAssist®, a minimally invasive percutaneous ventricular assist device, has passed the NMPA Innovative Medical Device review pathway and completed domestic clinical validation, with its technical performance gaining recognition in international academic forums.

From development to clinical deployment, these products are designed around domestic clinical realities, forming a localized life support system spanning multiple scenarios and reflecting the core value of high-tech enterprises—innovation in service of public health needs.

Global Recognition of China-Based Innovation

magAssist's domestic innovation efforts have also attracted international attention. The company has been shortlisted for the Prix Galien "Best Startup" nomination, and clinical trial data for NyokAssist® were presented at TCT 2025, receiving positive feedback from the global interventional cardiology community.

These international acknowledgements are not isolated initiatives, but rather a natural extension of domestic innovation reaching globally competitive standards, further validating the technical strength of China's high-tech medical device enterprises.

Looking Ahead: Advancing Localization with Responsibility and Purpose

The High-Tech Enterprise certification brings policy support, enhanced brand credibility, and talent attraction opportunities, while also reinforcing magAssist's responsibility to advance domestic innovation and localization.

Looking forward, magAssist will continue to increase R&D investment in China, focus on addressing critical bottleneck technologies in multi-organ life support, expand its localized product portfolio, and accelerate reimbursement coverage and clinical adoption nationwide—ensuring that advanced, independently developed medical technologies benefit a broader patient population.

This recognition represents both an authoritative endorsement of innovation capability and a responsibility aligned with the broader mission of medical device localization. Guided by its vision of "Technology in Motion, Life in Motion," magAssist remains committed to meeting urgent clinical needs, strengthening independent core technologies, and contributing to the high-quality development of China's medical device industry in support of the Healthy China initiative.